These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31791138)

  • 1. Implications for the monitoring of patients with multiple myeloma undergoing treatment with the anti-CD38 monoclonal daratumumab.
    Thirkettle S; Russell J; Wilson S; Ganijee T; Kulkarni S; Cavet J; Monaghan PJ
    Ann Clin Biochem; 2020 Mar; 57(2):178-181. PubMed ID: 31791138
    [No Abstract]   [Full Text] [Related]  

  • 2. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).
    van de Donk NW; Otten HG; El Haddad O; Axel A; Sasser AK; Croockewit S; Jacobs JF
    Clin Chem Lab Med; 2016 Jun; 54(6):1105-9. PubMed ID: 26812873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
    McCudden C; Axel AE; Slaets D; Dejoie T; Clemens PL; Frans S; Bald J; Plesner T; Jacobs JF; van de Donk NW; Moreau P; Schecter JM; Ahmadi T; Sasser AK
    Clin Chem Lab Med; 2016 Jun; 54(6):1095-104. PubMed ID: 27028734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference.
    Mills JR; Kohlhagen MC; Willrich MAV; Kourelis T; Dispenzieri A; Murray DL
    Blood; 2018 Aug; 132(6):670-672. PubMed ID: 29891533
    [No Abstract]   [Full Text] [Related]  

  • 5. Interference of monoclonal antibody therapies with serum protein electrophoresis tests.
    McCudden CR; Voorhees PM; Hainsworth SA; Whinna HC; Chapman JF; Hammett-Stabler CA; Willis MS
    Clin Chem; 2010 Dec; 56(12):1897-9. PubMed ID: 20940329
    [No Abstract]   [Full Text] [Related]  

  • 6. Incidence and Management of Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring.
    Liu L; Wertz WJ; Kondisko A; Shurin MR; Wheeler SE
    J Appl Lab Med; 2020 Jan; 5(1):29-40. PubMed ID: 32445341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A New Monoclonal Band in a Patient with Refractory Multiple Myeloma.
    Willard N; Bocsi GT
    Clin Chem; 2017 Apr; 63(4):927-935. PubMed ID: 28351858
    [No Abstract]   [Full Text] [Related]  

  • 8. Light-chain paraproteins with lupus anticoagulant activity.
    Yasin Z; Quick D; Thiagarajan P; Spoor D; Caraveo J; Palascak J
    Am J Hematol; 1999 Oct; 62(2):99-102. PubMed ID: 10509004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three monoclonal IgG components, an IgG4(lambda), an IgG2(kappa) and an IgG1/IgG3 (kappa) Gm(f,b) hybrid, in a single myeloma patient.
    Milosevic-Jovcic N; Dovezenski N; Jovanovic L; Rolovic Z; Gotic M; Radosevic N; Suvajdzic N; Tosic L
    Eur J Haematol; 1995 May; 54(5):288-95. PubMed ID: 7781753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paraprotein interference in an assay of conjugated bilirubin.
    Nauti A; Barassi A; Merlini G; d'Eril GV
    Clin Chem; 2005 Jun; 51(6):1076-7. PubMed ID: 15914800
    [No Abstract]   [Full Text] [Related]  

  • 11. Electrophoretic patterns post daratumumab.
    Sheldon J; Wheeler RD; Powles R
    Ann Clin Biochem; 2018 Mar; 55(2):299-301. PubMed ID: 28490184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma with monoclonal free IgG3 heavy chains and free kappa light chains.
    Richter AG; Harding S; Huissoon A; Drayson M; Pratt G
    Acta Haematol; 2010; 123(3):158-61. PubMed ID: 20215741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New strategies for MGUS and smoldering multiple myeloma.
    Kyle RA
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):507, 509. PubMed ID: 16163229
    [No Abstract]   [Full Text] [Related]  

  • 14. Transient paraproteinemia: an intriguing immunological anomaly.
    Strobel SL
    Ann Clin Lab Sci; 2003; 33(3):265-70. PubMed ID: 12956440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma.
    Rabut É; Castro-Fernandez A; Le Gall V; Meknache N
    Ann Biol Clin (Paris); 2017 Jun; 75(3):351-355. PubMed ID: 28540859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple myeloma and multiple plasmacytomas associated with free gamma heavy chain, free kappa light chain and IgGk paraproteins: an unusual triple gammopathy.
    Deighan WI; O'Kane MJ; McNicholl FP; Keren DF
    Ann Clin Biochem; 2016 Nov; 53(6):706-711. PubMed ID: 27166317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum-free light chain analysis: works in progress.
    Merlini G
    Clin Chem Lab Med; 2009; 47(9):1021-2. PubMed ID: 19728842
    [No Abstract]   [Full Text] [Related]  

  • 18. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
    Sanchez L; Wang Y; Siegel DS; Wang ML
    J Hematol Oncol; 2016 Jun; 9(1):51. PubMed ID: 27363983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
    Sherbenou DW; Mark TM; Forsberg P
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of the new Hevylite™ IgA assay for the diagnosis and follow-up of monoclonal gammopathies].
    Lakomy D; Lemaire-Ewing S; Denimal D; Bastie JN; Lafon I; Caillot D
    Ann Biol Clin (Paris); 2013; 71(2):157-63. PubMed ID: 23587579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.